The present invention relates to an siRNA targeting PRK2, which is a hepatitis C virus therapeutic agent, and can be effectively used as a hepatitis C virus therapeutic agent since the systemic delivery into a living body, particularly liver cells, is possible through an siRNA targeting a host PRK2 gene, which shows an anti-HCV activity, or a lipid formulation thereof.

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

Non-canonical substrates-acylated tRNA, introduction of non-canonical substrates into a peptide using ribosome catalysis, and method of preparing pharmacologically active motifs are disclosed. The present invention relates to acylated tRNA and introduction of pharmacologically active motif in peptide using ribosome-mediated catalysis and method that enables the production of a peptide having a cyclic motif without a complicated chemical process on an in vitro protein translation system.

The present invention relates to an siRNA targeting PRK2, which is a hepatitis C virus therapeutic agent, and can be effectively used as a hepatitis C virus therapeutic agent since the systemic delivery into a living body, particularly liver cells, is possible through an siRNA targeting a host PRK2 gene, which shows an anti-HCV activity, or a lipid formulation thereof.

Compositions and methods for improving expression of a recombinant protein or polypeptide of interest in a host cell are provided. Compositions comprising a polynucleotide coding sequence for a BTBooster are provided using a plant optimized system. The coding sequences can be used in vector constructs or expression systems for transformation and expression of a recombinant protein or polypeptide of interest in a host cell. Methods comprising the codon optimization of a polynucleotide coding sequence for increased expression in a bacterial host are provided. The codon optimization method can be used in designing a polynucleotide coding sequence which expresses robust levels of protein in a bacterial host cell.

Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Aceteylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat disease, disorders or conditions in an individual in need thereof.